Literature DB >> 9770519

Synthetic amino acid copolymers that bind to HLA-DR proteins and inhibit type II collagen-reactive T cell clones.

M Fridkis-Hareli1, E F Rosloniec, L Fugger, J L Strominger.   

Abstract

Copolymer 1 [poly(Y,E,A,K)] is a random synthetic amino acid copolymer of L-tyrosine, L-glutamic acid, L-alanine, and L-lysine that is effective both in suppression of experimental allergic encephalomyelitis and in the treatment of relapsing forms of multiple sclerosis. Copolymer 1 binds promiscuously and very efficiently to purified HLA-DR molecules within the peptide-binding groove. In the present study, YEAK and YEAK-related copolymers and type II collagen (CII) peptide 261-273, a candidate autoantigen in rheumatoid arthritis (RA), competed for binding to RA-associated HLA-DR molecules encoded by DRB1*0101 and DRB1*0401. Moreover, these copolymers (particularly YEAK, YAK, and YEK) inhibited the response of DR1- and DR4-restricted T cell clones to the CII epitope 261-273 by >50%. This direct evidence both for competitive interactions of these copolymers and CII peptide with RA-associated HLA-DR molecules and for inhibition of CII-specific T cell responses suggests that these compounds should be evaluated in animal models for rheumatoid arthritis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9770519      PMCID: PMC22864          DOI: 10.1073/pnas.95.21.12528

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  45 in total

1.  Definition of MHC and T cell receptor contacts in the HLA-DR4restricted immunodominant epitope in type II collagen and characterization of collagen-induced arthritis in HLA-DR4 and human CD4 transgenic mice.

Authors:  E C Andersson; B E Hansen; H Jacobsen; L S Madsen; C B Andersen; J Engberg; J B Rothbard; G S McDevitt; V Malmström; R Holmdahl; A Svejgaard; L Fugger
Journal:  Proc Natl Acad Sci U S A       Date:  1998-06-23       Impact factor: 11.205

2.  Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide.

Authors:  D Teitelbaum; A Meshorer; T Hirshfeld; R Arnon; M Sela
Journal:  Eur J Immunol       Date:  1971-08       Impact factor: 5.532

3.  Experimental arthritis in a nonhuman primate. I. Induction by bovine type II collagen.

Authors:  E S Cathcart; K C Hayes; W A Gonnerman; A A Lazzari; C Franzblau
Journal:  Lab Invest       Date:  1986-01       Impact factor: 5.662

4.  Suppression of experimental allergic encephalomyelitis in Rhesus monkeys by a synthetic basic copolymer.

Authors:  D Teitelbaum; C Webb; M Bree; A Meshorer; R Arnon; M Sela
Journal:  Clin Immunol Immunopathol       Date:  1974-11

5.  Effect of cyclophosphamide on suppressor cell activity in mice unresponsive to EAE.

Authors:  Z Lando; D Teitelbaum; R Arnon
Journal:  J Immunol       Date:  1979-11       Impact factor: 5.422

6.  Rheumatoid arthritis: a disease of T-lymphocyte/macrophage immunoregulation.

Authors:  G Janossy; G Panayi; O Duke; M Bofill; L W Poulter; G Goldstein
Journal:  Lancet       Date:  1981-10-17       Impact factor: 79.321

7.  A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis.

Authors:  M B Bornstein; A Miller; S Slagle; M Weitzman; H Crystal; E Drexler; M Keilson; A Merriam; S Wassertheil-Smoller; V Spada
Journal:  N Engl J Med       Date:  1987-08-13       Impact factor: 91.245

8.  Immunisation against heterologous type II collagen induces arthritis in mice.

Authors:  J S Courtenay; M J Dallman; A D Dayan; A Martin; B Mosedale
Journal:  Nature       Date:  1980-02-14       Impact factor: 49.962

9.  Autoimmunity to type II collagen an experimental model of arthritis.

Authors:  D E Trentham; A S Townes; A H Kang
Journal:  J Exp Med       Date:  1977-09-01       Impact factor: 14.307

10.  Inhibition of antigen-specific T lymphocyte activation by structurally related Ir gene-controlled polymers. Evidence of specific competition for accessory cell antigen presentation.

Authors:  K L Rock; B Benacerraf
Journal:  J Exp Med       Date:  1983-05-01       Impact factor: 14.307

View more
  6 in total

Review 1.  Oral tolerance with copolymer 1 for the treatment of multiple sclerosis.

Authors:  H L Weiner
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

Review 2.  Peptide-based immunotherapy of autoimmunity: a path of puzzles, paradoxes and possibilities.

Authors:  S M Anderton
Journal:  Immunology       Date:  2001-12       Impact factor: 7.397

Review 3.  Emerging opportunities for site-specific molecular and cellular interventions in autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2010-01-27       Impact factor: 3.199

Review 4.  Non-classical phenotypes of autoimmune hepatitis and advances in diagnosis and treatment.

Authors:  Albert J Czaja; Yusuf Bayraktar
Journal:  World J Gastroenterol       Date:  2009-05-21       Impact factor: 5.742

5.  CD8(+) T Cells Are Required For Glatiramer Acetate Therapy in Autoimmune Demyelinating Disease.

Authors:  Andrew F Tyler; Jason P Mendoza; Mihail Firan; Nitin J Karandikar
Journal:  PLoS One       Date:  2013-06-21       Impact factor: 3.240

Review 6.  Design of peptide immunotherapies for MHC Class-II-associated autoimmune disorders.

Authors:  Masha Fridkis-Hareli
Journal:  Clin Dev Immunol       Date:  2013-11-13
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.